Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • redhot47fla redhot47fla Mar 4, 2013 2:09 PM Flag

    Highlights of SGEN's investor presentation - 3/4/2013

    Here are just a few highlights of today’s presentation by SGEN CEO Clay Siegall during the Cowen & Company 33rd Annual Health Care Conference in Boston (my Internet access cut out and I missed the middle third of the session):

    - Another hint that we don’t have to worry about dilution. Siegall: “Seattle Genetics is in a very good financial position that can fund our future development very strongly.”

    - SGEN now has 1,200 accounts for Adcetris. Since approval, no patient has been denied coverage by any insurance company for on-label use of Adcetris.

    - Several trials and partnerships are producing actual or anticipated "exciting" results. (In the past, his use of the word "exciting" has foreshadowed good things).

    - Make of this what you will, but he made many mentions of Takeda. One of them: “They’ve been a great partner so far, with much more to come.”

    That's all I have. I don't think he broke any new ground, but - again - I missed a chunk of this presentation.

    You can listen to the replay through a link on the SGEN investor page.

 
SGEN
47.34-0.16(-0.34%)Jul 30 4:00 PMEDT